Skip to main content
padlock icon - secure page this page is secure

Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit

Buy Article:

$52.00 + tax (Refund Policy)

Dexmedetomidine, a highly selective and potent α2-adrenergic agonist, has a potentially useful role as a sedative agent in patients requiring intensive care. As part of a larger European multicentre trial, a total of 119 postoperative cardiac and general surgical patients requiring ventilation and sedation in an intensive care unit were enrolled in four centres in the United Kingdom. One hundred and five patients were randomly allocated to receive either dexmedetomidine or placebo with rescue sedation and analgesia provided by midazolam and morphine, respectively. Compared with the control group, intubated patients receiving dexmedetomidine required 80% less midazolam [mean 4.9 (5.8) μ−1.h−1 vs. 23.7 (27.5) μ−1.h−1, p < 0.0001], and 50% less morphine [11.2 (13.4) μ−1.h−1 vs. 21.5 (19.4) μ−1.h−1,p = 0.0006]. Cardiovascular effects and adverse events could be predicted from the known properties of alpha-2 agonists. In conclusion, dexmedetomidine is a useful agent for the provision of postoperative analgesia and sedation.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Dexmedetomidine; sedation; Intensive care; postoperative

Document Type: Research Article

Affiliations: 1: Department of Intensive Care, St George's Hospital, Blackshaw Road, London SW17 0QT, UK, 2: Department of Intensive Care, Bristol Royal Infirmary, Marlborough St, Bristol, UK, 3: Department of Intensive Care, University College Hospital, Mortimer St, London, UK, 4: Department of Intensive Care, St Thomas' Hospital, Lambeth Palace Rd, London, UK

Publication date: December 1, 1999

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more